Health Care/Hospital

The First US World-Class Bioscience Design Corporation Officially Launched

TAIPEI, Sept. 22, 2021 /PRNewswire/ --  TCI Co., Ltd. set up a subsidiary in the United States for the first time in 2019 to expand its business footprint and bring its successful experience inAsia to the United States. After two years of continuous effort, it has accumulated a series of extensiv...

2021-09-23 09:00 677

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

SUZHOU, China, and ROCKVILLE, MD, Sept 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor alrizomadlin (A...

2021-09-23 07:40 624

United Imaging Announces FDA Clearance for its Versatile Ultra-Premium Scanner, the uCT® ATLAS

HOUSTON, Sept. 22, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced FDA clearance for the uCT ATLAS, the latest in the company's Computed Tomography (CT) portfolio of scanners and the 25th FDA clearance for the company overall....

2021-09-22 21:00 734

Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest

* Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain) * Primary and secondary efficacy endpoints were successfully met * 100% efficacy against severe COVID-19 & hosp...

2021-09-22 18:56 605

Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA

INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seam...

2021-09-22 18:00 496

Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research

SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals announced the appointment of Dr.Alice Chen as Vice President, Discovery Biology and Head of Translational Research with effect fromSeptember 20, 2021. She will report to Dr.Kevin Pan, Founder and CEO of Asieris. Alice has over 20 ...

2021-09-22 14:45 520

New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA® (lurbinectedin) Approved in Singapore

Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved in Singapore to treat 2L metastatic small cell lung cancer (SCLC) in 20 years * ZEPZELCA provisional approval represents an important advance for adult patients whose metastatic SCLC has progressed on or after platinum-...

2021-09-22 14:30 570

Koji Tanabe, CEO of I Peace, Inc. honored by World Biz Magazine with "Top 100 Innovation CEO" Award

PALO ALTO, Calif., Sept. 21, 2021 /PRNewswire/ -- Koji Tanabe, Founder and CEO of I Peace, Inc. (https://www.ipeace.com  ), has been selected by the judges of World Biz Magazine's annual awards to be a recipient of the "Top 100 Innovation CEO – 2021" (https://www.worldbiz...

2021-09-22 02:00 598

FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis

RALEIGH, N.C., Sept. 21, 2021 /PRNewswire/ -- Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents. LEXETTE, a super potent topical corticosteroid, is now approved for the treatment ...

2021-09-21 22:00 3525

Origin Agritech and China Agricultural University to Collaborate on Research of Molecular Design of Corn Using CRISPR

BEIJING, Sept. 21, 2021 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED)  (the "Company" or "Origin"), an agriculture technology company, today announced that it has entered into collaboration agreement with China Agricultural University for the research of molecular design in corn. One of the...

2021-09-21 21:36 3683

Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021

MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was present...

2021-09-20 22:51 5899

PharmAbcine to Participate in BIO-Europe 2021

DAEJEON, South Korea, Sept. 20, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in the 27th annual BIO-Europe which will tak...

2021-09-20 20:00 611

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

* Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder * Phase 2 clinical trial on target to start by end of 2021 and expected to read out topline data by end of 2022 ADELAIDE, Australia, Sept....

2021-09-20 18:00 2664

Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

SHANGHAI, Sept. 19, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of digestive system tumors. Results of this trial have been ...

2021-09-20 08:24 3461

2021 CSCO | Henlius will Release Four Oral Presentations of Two Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar

SHANGHAI, Sept. 18, 2021 /PRNewswire/ -- The 24th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) will be held online and in-person from 25th to 29th September 2021. In this meeting, Henlius will release 4 study results of 2 products to be commercialized, the novel anti-PD-1 mAb ser...

2021-09-18 20:00 10609

Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021

SEOUL, South Korea, Sept. 17, 2021 /PRNewswire/ -- A leading medical AI provider Lunit today announced that its AI for tissue analysis has been applied in a clinical trial for drug development, accurately predicting the patients' response to immunotherapy. Including this major finding, the compan...

2021-09-17 21:00 861

InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355

BEIJING, Sept. 17, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies called Tiannuojiancheng Pharm...

2021-09-17 20:00 3263

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of Serplulimab Injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with carboplatin and albumin-bound ...

2021-09-17 20:00 3306

111, Inc. Announces Participation in the Cantor Virtual Global Healthcare Conference

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that Senior Vice President, Investor Relations and...

2021-09-17 19:00 3153

Zhongchao Inc. Launches Hematology MDT Training Platform to Improve Diagnosis and Treatment

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), an internet technology company offering healthcare professionals the online healthcare information, professional training and educational services platform and patients the patient management p...

2021-09-17 18:30 787
12345 ... 604